norgestrel has been researched along with Cardiovascular Diseases in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (58.33) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weisberg, E | 1 |
| Goldzieher, JW | 1 |
| Christie, T | 1 |
| Guillebaud, J | 1 |
| Haspels, AA | 1 |
| Punnonen, R; Rauramo, L; Vilska, S | 1 |
| Kay, CR | 1 |
| Niththyananthan, R; Wynn, V | 1 |
| Meade, TW | 1 |
| Greenberg, G; Meade, TW; Thompson, SG | 1 |
| Taskinen, MR | 1 |
| Sobel, NB | 1 |
| Crook, D; Godsland, IF; Lees, B; Stevenson, JC; Whitehead, MI | 1 |
| Oyelola, OO | 1 |
| Creatsas, G; Serfaty, D; Verougstraete, A; Wildemeersch, D | 1 |
| Al-Qattan, N; Omu, AE | 1 |
| Barnes, JF; Calder, A; Ekevall, K; Farish, E; Fletcher, CD; Hart, DM | 1 |
| Andersen, LF; Christiansen, E; Jespersen, J; Madsbad, S; Petersen, KR; Skouby, SO | 1 |
| Larsson-Cohn, U; Wallentin, L; Zador, G | 1 |
| Baz, CR | 1 |
| Dubnitskaia, LV; Korsakov, SG; Manuilova, IA | 1 |
| Keller, PJ | 1 |
| Hoppe, G | 1 |
2 review(s) available for norgestrel and Cardiovascular Diseases
| Article | Year |
|---|---|
Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages?
Topics: Breast Neoplasms; Cardiovascular Diseases; Desogestrel; Endometrium; Estrogen Replacement Therapy; Female; Humans; Norgestrel; Norpregnenes; Osteoporosis, Postmenopausal; Progesterone Congeners; Risk Factors; Structure-Activity Relationship | 1994 |
[Hormonal contraception using depot preparations].
Topics: Abnormalities, Drug-Induced; Blood Coagulation; Carbohydrate Metabolism; Cardiovascular Diseases; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levonorgestrel; Liver; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasms; Norethindrone; Norgestrel; Pregnancy; Risk | 1986 |
7 trial(s) available for norgestrel and Cardiovascular Diseases
| Article | Year |
|---|---|
The 150/30 formulation. Experience in the United Kingdom.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Contraceptives, Oral; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Middle Aged; Norgestrel; Risk; Smoking; Stereoisomerism; United Kingdom | 1983 |
Clinical experience with a low-dose contraceptive agent. European studies.
Topics: Adolescent; Adult; Amenorrhea; Body Weight; Cardiovascular Diseases; Clinical Trials as Topic; Contraceptives, Oral; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Ethinyl Estradiol; Europe; Female; Humans; Levonorgestrel; Middle Aged; Norgestrel; Pregnancy; Stereoisomerism | 1983 |
Oral versus transdermal hormone replacement therapy.
Topics: Administration, Cutaneous; Administration, Oral; Blood Glucose; Bone Density; Cardiovascular Diseases; Cholesterol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Insulin; Lipoproteins; Longitudinal Studies; Menopause; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Triglycerides; White People | 1993 |
Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Topics: Adult; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Lipids; Lipoproteins; Medroxyprogesterone Acetate; Nigeria; Norgestrel; Risk Factors | 1993 |
Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen.
Topics: Anabolic Agents; Apolipoproteins; Cardiovascular Diseases; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Middle Aged; Norgestrel; Norpregnenes; Postmenopause; Progesterone Congeners; Treatment Outcome | 1999 |
Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives.
Topics: Adult; Antibodies, Monoclonal; Blood Glucose; C-Peptide; Cardiovascular Diseases; Contraceptives, Oral, Synthetic; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Ethinyl Estradiol; Female; Fibrinolysis; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Norgestrel; Plasminogen Activator Inhibitor 1; Prospective Studies; Tissue Plasminogen Activator; Triglycerides | 1999 |
Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Contraceptives, Oral; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Lipoproteins, HDL; Norgestrel; Phospholipids; Pregnancy; Triglycerides | 1979 |
15 other study(ies) available for norgestrel and Cardiovascular Diseases
| Article | Year |
|---|---|
Contraceptive options for women in selected circumstances.
Topics: Adolescent; Adult; Anemia; Breast Diseases; Cardiovascular Diseases; Condoms; Contraception; Contraceptive Agents, Female; Contraindications; Desogestrel; Diabetes Mellitus; Drug Combinations; Drug Implants; Epilepsy; Ethinyl Estradiol; Female; Heart Valve Diseases; Humans; Hypertension; Inflammatory Bowel Diseases; Injections; Intrauterine Devices; Levonorgestrel; Liver Diseases; Lupus Erythematosus, Systemic; Medroxyprogesterone Acetate; Migraine Disorders; Norethindrone; Norgestrel; Obesity; Patient Preference; Pregnancy; Progestins; Stroke; Young Adult | 2010 |
Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol.
Topics: Cardiovascular Diseases; Contraceptives, Oral; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Ethinyl Estradiol; Female; Genital Neoplasms, Female; Humans; Levonorgestrel; Norgestrel; Stereoisomerism | 1983 |
Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
Topics: Body Weight; Cardiovascular Diseases; Contraceptives, Oral; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Norgestrel; Stereoisomerism | 1983 |
Long-term post-menopausal hormone therapy and serum HDL-C, total cholesterol and triglycerides.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Estradiol; Estriol; Estrogens; Female; Humans; Lipoproteins, HDL; Long-Term Care; Menopause; Middle Aged; Norgestrel; Triglycerides | 1983 |
Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Contraceptives, Oral; Contraceptives, Oral, Synthetic; England; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Lipoproteins, HDL; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Prospective Studies | 1982 |
The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Female; Humans; Levonorgestrel; Lipids; Lipoproteins, HDL; Norethindrone; Norethindrone Acetate; Norgestrel; Progesterone Congeners; Triglycerides | 1982 |
Effects of progestogens on the cardiovascular system.
Topics: Adult; Cardiovascular Diseases; Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Coronary Disease; Estrogens; Female; Humans; Hypertension; Levonorgestrel; Norethindrone; Norethindrone Acetate; Norgestrel; Progestins | 1982 |
Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.
Topics: Cardiovascular Diseases; Contraceptives, Oral; Dose-Response Relationship, Drug; Drug Combinations; Ethinyl Estradiol; Female; Humans; Norethindrone; Norgestrel; Thrombophlebitis | 1980 |
Postmenopausal hormone replacement therapy and plasma lipoproteins.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Double-Blind Method; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Norethindrone; Norethindrone Acetate; Norgestrel; Postmenopause; Progesterone Congeners; Progestins; Randomized Controlled Trials as Topic; Risk Factors | 1995 |
European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Topics: Adult; Aging; Cardiovascular Diseases; Contraception; Contraceptives, Oral; Data Collection; Desogestrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Estradiol Congeners; Ethinyl Estradiol; Europe; Female; Humans; Levonorgestrel; Norgestrel; Norpregnenes; Progesterone; Progesterone Congeners; Risk Factors; Smoking; Surveys and Questionnaires | 1995 |
Effect of postmenopausal estrogen replacement therapy on lipoproteins.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Drug Combinations; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoproteins; Middle Aged; Norgestrel; Risk Factors; Time Factors | 1996 |
Cilest (norgestimate/EE): some clinical observations.
Topics: Adult; Cardiovascular Diseases; Contraceptives, Oral, Combined; Female; Glucose; Humans; Norgestrel | 1992 |
[Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Chlormadinone Acetate; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Disease Susceptibility; Drug Combinations; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combination; Female; Humans; Hypertension; Middle Aged; Norethindrone; Norgestrel; Risk Factors | 1989 |
Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Contraceptives, Oral, Synthetic; Desogestrel; Female; Humans; Levonorgestrel; Lipoproteins; Norethindrone; Norgestrel; Norpregnenes; Population Surveillance; Progesterone Congeners; Prospective Studies; Risk | 1987 |
Oral contraception, 1986. Endocrinology and pharmacology. A panel discussion.
Topics: Adult; Animals; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Contraceptives, Oral, Synthetic; Drug Administration Schedule; Ethinyl Estradiol; Female; Genital Neoplasms, Female; Humans; Mestranol; Middle Aged; Norethindrone; Norgestrel; Rats; Risk | 1986 |